Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2110311 | 0.78 | MMP1 (0.36) | MMP1MMP8CA12CA1CA2 | |
| SCHEMBL848769 | 0.73 | MMP2 (0.31) | MMP8MMP2 | |
| SCHEMBL187536 | 0.70 | — | — | |
| SCHEMBL2874752 | 0.70 | GRIK1 (0.34) | — | |
| SCHEMBL27750636 | 0.68 | CA4 (0.33) | — | |
| SCHEMBL5037125 | 0.68 | MMP1 (0.33) | MMP1MMP8CA12CA1CA2 | |
| SCHEMBL18486496 | 0.62 | MMP1 (0.37) | MMP1MMP8CA12CA1CA2 | |
| SCHEMBL165032 | 0.62 | LAP3 (0.30) | — | |
| SCHEMBL109960 | 0.61 | TSHR (0.41) | — | |
| SCHEMBL3469330 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390644-B2 | Raman tag | PURDUE RESEARCH FOUNDATION (US) | 2022-07-19 | — | — | US | claimed |
| US-20190085019-A1 | RAMAN TAG | PURDUE RESEARCH FOUNDATION (US) | 2019-03-21 | — | — | US | claimed |
| EP-2785687-B1 | PROCESS FOR PREPARATION OF (3R)-2,4-DI-LEAVING GROUP-3-METHYLBUT-1-ENE | SANDOZ AG (CH) | 2019-02-20 | — | — | EP | claimed |
| US-10131687-B2 | Raman tag | PURDUE RESEARCH FOUNDATION (US) | 2018-11-20 | — | — | US | claimed |
| US-20170313738-A1 | RAMAN TAG | PURDUE RESEARCH FOUNDATION (US) | 2017-11-02 | — | — | US | claimed |
| US-9181152-B2 | Process for preparation of (3R)-2,4-di-leaving group-3-methylbut-1-ene | ALPHORA RESEARCH INC. (CA) | 2015-11-10 | — | — | US | claimed |
| US-20140323744-A1 | PROCESS FOR PREPARATION OF (3R)-2,4-DI-LEAVING GROUP-3-METHYLBUT-1-ENE | ALPHORA RESEARCH INC. (CA) | 2014-10-30 | — | — | US | claimed |
| EP-2785687-A1 | PROCESS FOR PREPARATION OF (3R)-2,4-DI-LEAVING GROUP-3-METHYLBUT-1-ENE | Alphora Research Inc. (CA) | 2014-10-08 | — | — | EP | claimed |
| WO-2014001527-A2 | LIPID ANALYSIS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2014-01-03 | — | — | WO | claimed |
| WO-2013078559-A1 | PROCESS FOR PREPARATION OF (3R)-2,4-DI-LEAVING GROUP-3-METHYLBUT-1-ENE | ALPHORA RESEARCH INC. (CA) | 2013-06-06 | — | — | WO | claimed |
| US-7973165-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-05 | — | — | US | claimed |
| EP-1353929-B1 | STREPTOGRAMIN DERIVATIVES PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2005-03-16 | — | — | EP | claimed |
| US-20260137674-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITOR | INCYTE CORP (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4743178-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4745129-A2 | COMPOUND HAVING CYCLIC STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743447-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| WO-2000035908-A1 | 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2 | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| EP-0944587-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-09-29 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1998024759-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313738-A1 | RAMAN TAG | CD2, DNAJA3, DNAJC10 | MMP1 4264/4885MMP8 4490/4885CA12 3120/4885 |
| US-20260137674-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITOR | KRAS, NRAS, DCTD | MMP1 3501/4885MMP8 2179/4885CA12 4347/4885 |
| US-11390644-B2 | Raman tag | NR1H4, PDS5A, DHCR7 | MMP1 4562/4885MMP8 4754/4885CA12 1129/4885 |
| US-10131687-B2 | Raman tag | NR1H4, DOHH, DHCR7 | MMP1 4552/4885MMP8 4738/4885CA12 981/4885 |
| US-20140323744-A1 | PROCESS FOR PREPARATION OF (3R)-2,4-DI-LEAVING GROUP-3-METHYLBUT-1-ENE | ALG8, LSS, GYPA | MMP1 4336/4885MMP8 4319/4885CA12 2946/4885 |
| US-20190085019-A1 | RAMAN TAG | NR1H4, NR1H2, NR1H3 | MMP1 4347/4885MMP8 3973/4885CA12 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.